Announcement from the Central Commission for Discipline Inspection: A batch of pharmaceutical companies involved in pharmaceutical rebates

In the early morning of October 17th, the Central Commission for Discipline Inspection of the Communist Party of China (CPC) issued a headline article, "Strictly check the right to money transactions, establish a list of misinsent, concentrate on volume procurement, and cut off the chain of medical bribery interests."
The author found that since this year disclosed corruption cases in the medical field, the collection of drug supplies rebate problem appears the most frequently, showing the high amount of money involved, corruption interest chain link and so on, resulting in high prices of drugs and medical supplies, medical costs too fast growth, a large number of loss of medical insurance funds and other issues, increasing the burden of patients, infringe on the vital interests of the masses, it is urgent to fight.
The State Health Insurance Administration price recruitment department responsible person said, according to the publicly accessible court judgment documents statistics, between 2016 and 2019, more than half of the country's 100 compulsory drug enterprises were found to have directly or indirectly given kickbacks, of which the most frequent enterprises involved in more than 20 cases in three years, a single case rebate amount of more than 20 million yuan.
is it so difficult to eradicate drug bribery? Several industry experts say the concentration of power and the lack of effective regulation are the most immediate reasons.
addition, the past "recruitment and separation" of drug procurement model, but also caused by the prohibition of pharmaceutical bribery one of the reasons.
2006, the National Development and Reform Commission issued the Opinions on Further Rectifying the Market Price Order of Medicines and Medical Services, which stipulates that medical institutions at or above the county level can charge a 15% increase in the rate of drug sales.
with the deepening of the reform of the medical and health system, the drug increase has now been completely abolished.
Although the retail discount rate of drugs is strictly limited, but because of the decentralized procurement model there is only the problem of price without volume, volume price decoupling, enterprises lack sales expectations, in order to obtain higher returns, often take the initiative to pay bribes to the hospital, the winning bid will be high.
Credit rating, generating a strong deterrent effect In order to combat non-compliance, the State Health Insurance Administration officially issued the "Pharmaceutical Price and Credit Evaluation Operating Standards (Draft for Comments)" and "Pharmaceutical Price and Credit Rating Discretionary Benchmark (Draft for Comments)," the plan is to establish a system of pharmaceutical prices and credit evaluation, will receive rebates, monopoly control and marketing of drug prices to attract credit and directly bound to pharmaceutical enterprises nationwide, and through the way of credit rating to affect the follow-up of pharmaceutical enterprises.
And the article believes that the above-mentioned documents require all regions by the end of 2020 to establish and implement a credit evaluation system, involving medical commercial bribery and other seven kinds of unconscionable behavior of pharmaceutical enterprises will be included in the "black list" of disrelievers, that is, the National Health Insurance Administration to promote the innovation of the credit evaluation system, increased the fight against bribery.
purchase and sale of medicines, giving rebates or other improper benefits to all kinds of medical institutions, centralized purchasing agencies and their staffs at all levels" ranks first among the main cases of disreencing.
Pharmaceutical enterprises will face written reminders and warnings, relying on centralized procurement platform to remind buyers of risk information, limit or suspend the relevant drugs or medical supplies hanging on the network, limit or suspend the procurement of related drugs or medical supplies, disclosure of disincance information and other disposal measures, misinrepishment involving the number of provinces to meet the prescribed conditions, will also be initiated by the State Health Insurance Administration pharmaceutical prices and tender procurement guidance center national joint disposal.
In this regard, the National Health Insurance Administration price recruitment department responsible person said, "pharmaceutical enterprises are often insensitive to rebate cases of fines, but to give rebates will lead to the loss of access to the centralized procurement market opportunities, will produce a strong deterrent effect, thus forming a system of governance effect."
" in addition, experts said, "the 'black list' in the past to draw price and marketing red lines, express the risk of loss of trust, pull up the live high-voltage line, from the point of view of combating bribery is of great significance."
" In the future, we should establish cooperation mechanisms and regular notification systems, break down information barriers between departments, promote information exchange and sharing at all levels of the system, and enhance the accuracy and authority of the "blacklist".
drug rebate problem, exposure frequency from April this year, the Central Commission for Discipline Inspection issued a number of topic articles related to the field of medicine, basically for drug rebates.
is an accurate signal that drug rebates are the focus of its future work, with the gradual implementation of the system of pharmaceutical prices and credit evaluation.
the non-compliance of pharmaceutical representatives can pose greater risks to pharmaceutical companies.
To some extent, the Health Insurance Bureau from the recruitment side to establish a mechanism to combat drug bribery, health care commission from the hospital use side to strengthen the strict investigation of pharmaceutical purchase and sale behavior, more relevant departments are also in the purchase and sale of medicine heavy gold sales and other issues issued the corresponding policy documents.
and Cypress Blue searched for "drug rebates" on the legal document website "openlaw", with a total of 3,801 results involving a number of well-known pharmaceutical companies.
Among them, Guangdong, Anhui, Fujian, Hunan and other places are the worst-hit areas of drug rebate cases, as a region rich in medical resources, pharmaceutical terminals determine the market trend, and doctors, nurses, pharmacists, inspectors and other medical and health personnel are the main talent resources in the medical market, they really determine the sales of pharmaceutical varieties.
these talents are mainly distributed in the central and eastern coastal areas, Sichuan and Guangdong, making cases in these areas more frequent and more effective.
that is to say, non-compliant pharmaceutical purchases and sales for pharmaceutical representatives of individuals as well as pharmaceutical companies, the risk is also increasing as the relevant departments continue to crack down.
if there is a problem, both pharmaceutical representatives and pharmaceutical companies will face unprecedented trouble.
.